800 related articles for article (PubMed ID: 27751442)
1. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.
Khanna MR; Kovalevich J; Lee VM; Trojanowski JQ; Brunden KR
Alzheimers Dement; 2016 Oct; 12(10):1051-1065. PubMed ID: 27751442
[TBL] [Abstract][Full Text] [Related]
2. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.
Riku Y; Iwasaki Y; Ishigaki S; Akagi A; Hasegawa M; Nishioka K; Li Y; Riku M; Ikeuchi T; Fujioka Y; Miyahara H; Sone J; Hattori N; Yoshida M; Katsuno M; Sobue G
Brain; 2022 Aug; 145(8):2769-2784. PubMed ID: 35274674
[TBL] [Abstract][Full Text] [Related]
3. [Neuroprotective treatment of tauopathies].
Respondek G; Krey L; Huber M; Pflugrad H; Wegner F; Höglinger GU
Nervenarzt; 2021 Dec; 92(12):1227-1238. PubMed ID: 34652482
[TBL] [Abstract][Full Text] [Related]
4. The Role of Tau Proteoforms in Health and Disease.
Waheed Z; Choudhary J; Jatala FH; Fatimah ; Noor A; Zerr I; Zafar S
Mol Neurobiol; 2023 Sep; 60(9):5155-5166. PubMed ID: 37266762
[TBL] [Abstract][Full Text] [Related]
5. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
[TBL] [Abstract][Full Text] [Related]
6. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies.
Brunden KR; Yao Y; Potuzak JS; Ferrer NI; Ballatore C; James MJ; Hogan AM; Trojanowski JQ; Smith AB; Lee VM
Pharmacol Res; 2011 Apr; 63(4):341-51. PubMed ID: 21163349
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.
Rawat P; Sehar U; Bisht J; Selman A; Culberson J; Reddy PH
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361631
[TBL] [Abstract][Full Text] [Related]
9. [Neuropathology of tauopathy].
Yoshida M
Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic landscape of tauopathies: challenges and prospects.
Cummings JL; Gonzalez MI; Pritchard MC; May PC; Toledo-Sherman LM; Harris GA
Alzheimers Res Ther; 2023 Oct; 15(1):168. PubMed ID: 37803386
[TBL] [Abstract][Full Text] [Related]
11. Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau).
Gibbons GS; Kim SJ; Robinson JL; Changolkar L; Irwin DJ; Shaw LM; Lee VM; Trojanowski JQ
Acta Neuropathol Commun; 2019 Mar; 7(1):34. PubMed ID: 30832741
[TBL] [Abstract][Full Text] [Related]
12. Targeting tau: Clinical trials and novel therapeutic approaches.
VandeVrede L; Boxer AL; Polydoro M
Neurosci Lett; 2020 Jul; 731():134919. PubMed ID: 32380145
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathogenesis of the Tauopathies.
Götz J; Halliday G; Nisbet RM
Annu Rev Pathol; 2019 Jan; 14():239-261. PubMed ID: 30355155
[TBL] [Abstract][Full Text] [Related]
14. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
Stancu IC; Ferraiolo M; Terwel D; Dewachter I
Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
[TBL] [Abstract][Full Text] [Related]
15. The neuropathological spectrum of neurodegenerative tauopathies.
Tolnay M; Probst A
IUBMB Life; 2003 Jun; 55(6):299-305. PubMed ID: 12938731
[TBL] [Abstract][Full Text] [Related]
16. Disease-modifying therapies for tauopathies: agents in the pipeline.
Panza F; Imbimbo BP; Lozupone M; Greco A; Seripa D; Logroscino G; Daniele A; Colosimo C
Expert Rev Neurother; 2019 May; 19(5):397-408. PubMed ID: 30973276
[TBL] [Abstract][Full Text] [Related]
17. Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies.
Pires G; McElligott S; Drusinsky S; Halliday G; Potier MC; Wisniewski T; Drummond E
Acta Neuropathol Commun; 2019 Dec; 7(1):195. PubMed ID: 31796108
[TBL] [Abstract][Full Text] [Related]
18. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
[TBL] [Abstract][Full Text] [Related]
19. Tauopathies as clinicopathological entities.
Irwin DJ
Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(0 1):S29-33. PubMed ID: 26382841
[TBL] [Abstract][Full Text] [Related]
20. Development of a novel tau propagation mouse model endogenously expressing 3 and 4 repeat tau isoforms.
Hosokawa M; Masuda-Suzukake M; Shitara H; Shimozawa A; Suzuki G; Kondo H; Nonaka T; Campbell W; Arai T; Hasegawa M
Brain; 2022 Mar; 145(1):349-361. PubMed ID: 34515757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
